SLCTR_2008_006
Study of Abetimus Sodium in Lupus Patients With History of Renal Disease
A randomized, double blind, placebo-controlled, three arm, parallel group, multicenter, multinational safety and efficacy trial of 300 mg and 900 mg of abetimus sodium in systemic lupus erythematosus (SLE) patients with a history of renal disease
La Jolla Pharmaceutical Company·Not Applicable·Sri Lanka Clinical Trials RegistryTerminated
Study focus
- Disease/Condition
- Systemic Lupus Erythematosus
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- La Jolla Pharmaceutical Company
- Location
- Argentina, Belarus, Brazil, Czech Republic, Georgia, Germany, HongKong, Hungary, India, Indonesia, N
Timeline & enrollment
- Phase
- Not Applicable
- Start date
- May 06, 2008
- End date
- N/A
ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
- Registry
- Sri Lanka Clinical Trials Registry
- Trial ID
- SLCTR_2008_006
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for SLCTR_2008_006 through Pure Global AI's free database. This Not Applicable trial is sponsored by La Jolla Pharmaceutical Company and is currently Terminated. The study focuses on Systemic Lupus Erythematosus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.